Plasma thromboxane and prostacyclin are linear related and increased in patients presenting with acute myocardial infarction.

The role of prostanoids in patients with ischemic heart disease including acute myocardial infarction (AMI) has been recognized. However, there is very limited knowledge of the baseline TXB2 and 6-keto-PGF1a plasma levels in patients with AMI before therapy has been administered. We compared plasma levels of TXB2 and 6-keto-PGF1a by enzyme immunoassay in 18 AMI patients before thrombolysis, with those of 13 healthy controls. Plasma levels of TXB2 (319.78+/-16.50 pg/ml) and 6-keto-PGF1a (536.72+/-56.71 pg/ml) were heterogeneous, but significantly higher in the AMI patients than in controls (175.92+/-17.29 pg/ml and 192.08+/-26.11 pg/ml, respectively). In some patients, long-term aspirin therapy mildly inhibits baseline prostanoid levels, however, limited data prevents us from further speculations on this issue. Although, the contributions by prostanoids to the pathogenesis of AMI have been well proposed, their plasma concentrations are not uniformly elevated, and it is still unclear whether the resultant changes are indicative of clinically meaningful effects.

Duke Scholars

Author Paul Alfred Gurbel Medicine, Clinical Pharmacology